Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways (Articolo in rivista) (literal)

Anno

• 2012-01-01T00:00:00+01:00 (literal)

Alternative label

• Paratore, Sabrina; Pezzino, Salvatore; Cavallaro, Sebastiano (2012)
  Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
  in Current genomics
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Paratore, Sabrina; Pezzino, Salvatore; Cavallaro, Sebastiano (literal)

Pagina inizio

• 321 (literal)

Pagina fine

• 333 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 13 (literal)

Rivista

• Current genomics (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

• 13 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 4 (literal)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Italian Natl Res Council; University of Catania (literal)

Titolo

• Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways (literal)

Abstract

• Amyotrophic Lateral Sclerosis (ALS) is a progressive and disabling neurodegenerative disorder characterized by upper and lower motor neuron loss, leading to respiratory insufficiency and death after 3-5 years. Riluzole is currently the only FDA approved drug for ALS, but it has only modest effects on survival. The majority of ALS cases are sporadic and probably associated to a multifactorial etiology. With the completion of genome sequencing in humans and model organisms, together with the advent of DNA microarray technology, the transcriptional cascades and networks underlying neurodegeneration in ALS are being elucidated providing new potential pharmacological targets. The main challenge now is the effective screening of the myriad of targets to identify those with the most therapeutic utility. The present review will illustrate how the identification, prioritization and validation of preclinical therapeutics can be achieved through genomic analysis of critical pathways and networks deregulated in ALS pathology. (literal)

Prodotto di

• Genomica funzionale delle malattie ereditarie del sistema nervoso (ME.P05.010.001) (Modulo)
• Institute of neurological sciences (ISN) (Istituto)

Autore CNR

• SABRINA PARATORE (Unità di personale esterno)
• SEBASTIANO CAVALLARO (Unità di personale interno)

Insieme di parole chiave

• Keywords of "Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways" (Insieme di parole chiave)

Incoming links:

Autore CNR di

• SEBASTIANO CAVALLARO (Unità di personale interno)
• SABRINA PARATORE (Unità di personale esterno)

Prodotto

• Institute of neurological sciences (ISN) (Istituto)
• Genomica funzionale delle malattie ereditarie del sistema nervoso (ME.P05.010.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Current genomics (Rivista)

Insieme di parole chiave di

• Keywords of "Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways" (Insieme di parole chiave)